Impact of neutrophil-to-lymphocyte ratio on periprocedural myocardial infarction in patients undergoing non-urgent percutaneous coronary revascularisation

Netherlands Heart Journal

Volumn 24, Issue 7-8, 2016, Pages 462-474

  Verdoia, M ^a   Schaffer, A ^a   Barbieri, L ^a   Di Giovine, G ^a   Bellomo, G ^a   Marino, P ^a   Suryapranata, H ^b   De Luca, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Neutrophil lymphocyte ratio; PCI; Periprocedural myocardial infarction; White blood cells

Indexed keywords

CLOPIDOGREL; TICAGRELOR; TROPONIN I;

ACUTE CORONARY SYNDROME; ARTICLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MUSCLE NECROSIS; NEUTROPHIL LYMPHOCYTE RATIO; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY;

EID: 84979656110     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-016-0850-6     Document Type: Article

References (35)

1. Navarese EP, Luca G de, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011; 9: 1902-1915.
2. Luca G de, Smit JJ, Ernst N, et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost. 2005; 93: 820-823.
3. Capozzolo C, Piscione F, Luca G de, et al. Direct coronary stenting: effect on coronary blood flow, immediate and late clinical results. Catheter Cardiovasc Interv. 2001; 53: 464-473.
4. Cuculi F, Lim CC, Banning AP. Periprocedural myocardial injury during elective coronary intervention: is it important and how can it be prevented? Heart. 2010; 96: 736-740.
5. Hanna EB, Hennebry TA. Periprocedural myocardial infarction: review and classification. Clin Cardiol. 2010; 33: 476-483.
6. Michaels AD, Gibson CM, Barron HV. Microvascular dysfunction in acute myocardial infarction: focus on the roles of platelet and inflammatory mediators in the no-reflow phenomenon. Am J Cardiol. 2000; 85: 50b-60b.
7. Shah N, Parikh V, Patel N, et al. Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: Insights from the National Health and Nutrition Examination Survey-III. Int J Cardiol. 2014; 171: 390-397.
8. Park BJ, Shim JY, Lee HR, et al. Relationship of neutrophil-lymphocyte ratio with arterial stiffness and coronary calcium score. Clin Chim Acta. 2011; 412: 925-929.
9. Fowler AJ, Agha RA. Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography - the growing versatility of NLR. Atherosclerosis. 2013; 228: 44-45.
10. Yilmaz M, Tenekecioglu E, Arslan B, et al. White Blood Cell Subtypes and Neutrophil-Lymphocyte Ratio in Prediction of Coronary Thrombus Formation in Non-ST-Segment Elevated Acute Coronary Syndrome. Clin Appl Thromb Hemost. 2015; 21: 446-452.
11. Sawant AC, Adhikari P, Narra SR, et al. Neutrophil to lymphocyte ratio predicts short and long term mortality following revascularization therapy for ST elevation myocardial infarction. Cardiol J. 2014; 21: 500-508.
12. Han YC, Yang TH, Kim DI, et al. Neutrophil to Lymphocyte Ratio Predicts Long-Term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Korean Circ J. 2013; 43: 93-99.
13. Luca G de, Santagostino M, Secco GG, et al. Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis. 2009; 206: 292-297.
14. Luca G de, Secco GG, Santagostino M, et al. Novara Atherosclerosis Study Group (NAS). Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis. 2012; 22: 426-433.
15. Luca G de, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analyis of randomised trials. Thromb Haemost. 2009; 102: 428-436.
16. Postma S, Dambrink JH, Boer MJ de, et al. The influence of residential distance on time to treatment in ST-elevation myocardial infarction patients. Neth Heart J. 2014; 22: 513-519.
17. Luca G de, Ernst N, van’t Hof AW, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J. 2006; 151: 1256-1259.
18. Luca G de, Małek LA, Maciejewski P, et al. STEMI 2003 Registry Collaborators. Impact of diabetes on survival in patients with STsegment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. Atherosclerosis. 2010; 210: 516-520.
19. Luca G de, Gibson CM, Bellandi F, et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. Atherosclerosis. 2009; 207: 181-185.
20. Luca G de, Ernst N, Suryapranata H, et al. Relation of interhospital delay and mortality in patients with ST-segment elevation myocardial infarction transferred for primary coronary angioplasty. Am J Cardiol. 2005; 95: 1361-1363.
21. Rasoul S, Ommen V van, Vainer J, et al. Multivessel revascularisation versus infarct-related artery only revascularisation during the index primary PCI in STEMI patients with multivessel disease: a meta-analysis. Neth Heart J. 2015; 23: 224-231.
22. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. Circulation. 2005; 111: 1027-1032.
23. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997; 96: 396-399.
24. Becatti M, Fiorillo C, Gori AM, et al. Platelet and leukocyte ROS production and lipoperoxidation are associated with high platelet reactivity in Non-ST elevation myocardial infarction (NSTEMI) patients on dual antiplatelet treatment. Atherosclerosis. 2013; 231: 392-400.
25. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation. 2011; 123: 551-565.
26. Prasad A, StoneGW, Stuckey TD, et al. Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty. Am J Cardiol. 2007; 99: 1067-1071.
27. Husser O, Bodi V, Sanchis J, et al. White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance-derived infarct size and impact on outcome. Inflammation. 2011; 34: 73-84.
28. Cantor H, Simpson E. Regulation of the immune response by subclasses of T lymphocytes. I. Interactions between pre-killer T cells and regulatory T cells obtained from peripheral lymphoid tissues of mice. Eur J Immunol. 1975; 5: 330-336.
29. Duffy BK, Gurm HS, Rajagopal V, et al. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2006; 97: 993-996.
30. Tamhane UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol. 2008; 102: 653-657.
31. Ergelen M, Uyarel H, Altay S, et al. Predictive Value of Elevated Neutrophil to Lymphocyte Ratio in Patients Undergoing Primary Angioplasty for ST-Segment Elevation Myocardial Infarction. Clin Appl Thromb Hemost. 2014; 20: 427-432.
32. Akpek M, Kaya MG, Lam YY, et al. Relation of neutrophil/ lymphocyte ratio to coronary flow to in-hospital major adverse cardiac events in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012; 110: 621-627.
33. Soylu K, Yuksel S, Gulel O, et al. The relationship of coronary flow to neutrophil/lymphocyte ratio in patients undergoing primary percutaneous coronary intervention. J Thorac Dis. 2013; 5: 258-264.
34. Sardella G, Lucisano L, Mancone M, et al. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013; 168: 3715-3720.
35. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study. Am Heart J. 2014; 168: 792-797.